Frequency and spectrum of mutations at codons 12 and 13 of the c-K-ras gene in human tumors
- PMID: 1685441
- PMCID: PMC1568052
- DOI: 10.1289/ehp.9193125
Frequency and spectrum of mutations at codons 12 and 13 of the c-K-ras gene in human tumors
Abstract
The frequency of point mutations at codons 12 and 13 of the c-K-ras gene has been determined in a panel of more than 400 human tumors. Mutant c-K-ras genes were detected in about 75% of adenocarcinomas of the pancreas (n = 84); 40% of adenomas (n = 72) and carcinomas (n = 244) of the colon end rectum; 30% of carcinomas of the bile duct (n = 19); 25% of carcinomas of the lung (n = 92), and in lower frequency in other carcinomas, including liver, stomach, and kidney. No mutations were found in carcinomas of the breast, prostate, esophagus, and gall bladder, among others. Comparative analysis of the spectrum of mutations show that while G to A transitions were the most frequent mutations in pancreatic and colo-rectal tumors, G to T transversions were more prevalent in lung carcinomas. The aspartic acid mutation at codon 13 (GGC----GAC) was relatively frequent in colo-rectal tumors but rare in pancreatic and lung carcinomas. The differences in the mutation spectrum of the c-K-ras gene in cancers of the gastrointestinal and respiratory tracts are suggestive of differential exposure to genotoxic agents.
Similar articles
-
Mutations of K-ras oncogene and absence of H-ras mutations in squamous cell carcinomas of the lung.Clin Cancer Res. 1995 Mar;1(3):359-65. Clin Cancer Res. 1995. PMID: 9815992
-
K-ras activation in non-small cell lung cancer in the dog.Cancer Res. 1992 Sep 1;52(17):4724-7. Cancer Res. 1992. PMID: 1324792
-
GTP-binding proteins as oncogenes in human tumors.Environ Health Perspect. 1991 Jun;93:17-8. doi: 10.1289/ehp.919317. Environ Health Perspect. 1991. PMID: 1773789 Free PMC article. Review. No abstract available.
-
Activation of K-ras by codon 13 mutations in C57BL/6 X C3H F1 mouse tumors induced by exposure to 1,3-butadiene.Cancer Res. 1990 Aug 1;50(15):4818-23. Cancer Res. 1990. PMID: 2196119
-
K-ras oncogene activation in adenocarcinoma of the human pancreas. A study of 82 carcinomas using a combination of mutant-enriched polymerase chain reaction analysis and allele-specific oligonucleotide hybridization.Am J Pathol. 1993 Aug;143(2):545-54. Am J Pathol. 1993. PMID: 8342602 Free PMC article. Review.
Cited by
-
A Pterin-FAM-TAMRA Tri-color Fluorescence Biosensor to Detect the Level of KRAS Point Mutation.Anal Sci. 2020 Dec 10;36(12):1529-1533. doi: 10.2116/analsci.20P265. Epub 2020 Aug 21. Anal Sci. 2020. PMID: 32830162
-
Detection of K-ras Mutations in Predicting Efficacy of Epidermal Growth Factor Receptor Tyrosine Kinase (EGFR-TK) Inhibitor in Patients with Metastatic Colorectal Cancer.PLoS One. 2015 May 7;10(5):e0101019. doi: 10.1371/journal.pone.0101019. eCollection 2015. PLoS One. 2015. PMID: 25950441 Free PMC article.
-
K-Ras mutations and benign pancreatic disease.Int J Pancreatol. 2000 Apr;27(2):93-103. doi: 10.1385/IJGC:27:2:093. Int J Pancreatol. 2000. PMID: 10862508 Review.
-
The complexity of prostate cancer: genomic alterations and heterogeneity.Nat Rev Urol. 2012 Nov;9(11):652-64. doi: 10.1038/nrurol.2012.185. Nat Rev Urol. 2012. PMID: 23132303 Review.
-
Sequence-directed base mispairing in human oncogenes.Mol Cell Biol. 1998 Aug;18(8):4659-69. doi: 10.1128/MCB.18.8.4659. Mol Cell Biol. 1998. PMID: 9671476 Free PMC article.
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous